282 related articles for article (PubMed ID: 22995909)
1. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency.
Bouchecareilh M; Hutt DM; Szajner P; Flotte TR; Balch WE
J Biol Chem; 2012 Nov; 287(45):38265-78. PubMed ID: 22995909
[TBL] [Abstract][Full Text] [Related]
2. Measuring the Effect of Histone Deacetylase Inhibitors (HDACi) on the Secretion and Activity of Alpha-1 Antitrypsin.
Wang C; Bouchecareilh M; Balch WE
Methods Mol Biol; 2017; 1639():185-193. PubMed ID: 28752458
[TBL] [Abstract][Full Text] [Related]
3. [Alpha-1-antitrypsin deficiency].
Bouchecareilh M
Med Sci (Paris); 2014 Oct; 30(10):889-95. PubMed ID: 25311024
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response.
Hidvegi T; Schmidt BZ; Hale P; Perlmutter DH
J Biol Chem; 2005 Nov; 280(47):39002-15. PubMed ID: 16183649
[TBL] [Abstract][Full Text] [Related]
5. SAHA enhances Proteostasis of epilepsy-associated α1(A322D)β2γ2 GABA(A) receptors.
Di XJ; Han DY; Wang YJ; Chance MR; Mu TW
Chem Biol; 2013 Dec; 20(12):1456-68. PubMed ID: 24211135
[TBL] [Abstract][Full Text] [Related]
6. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
7. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
8. Proteostasis strategies for restoring alpha1-antitrypsin deficiency.
Bouchecareilh M; Conkright JJ; Balch WE
Proc Am Thorac Soc; 2010 Nov; 7(6):415-22. PubMed ID: 21030523
[TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo.
Dincman TA; Beare JE; Ohri SS; Gallo V; Hetman M; Whittemore SR
Int J Dev Neurosci; 2016 Nov; 54():53-61. PubMed ID: 27587342
[TBL] [Abstract][Full Text] [Related]
12. Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction network.
Sardiu ME; Smith KT; Groppe BD; Gilmore JM; Saraf A; Egidy R; Peak A; Seidel CW; Florens L; Workman JL; Washburn MP
Mol Cell Proteomics; 2014 Nov; 13(11):3114-25. PubMed ID: 25073741
[TBL] [Abstract][Full Text] [Related]
13. Discovery of an inhibitor of Z-alpha1 antitrypsin polymerization.
Berthelier V; Harris JB; Estenson KN; Baudry J
PLoS One; 2015; 10(5):e0126256. PubMed ID: 25961288
[TBL] [Abstract][Full Text] [Related]
14. Endoplasmic reticulum polymers impair luminal protein mobility and sensitize to cellular stress in alpha1-antitrypsin deficiency.
Ordóñez A; Snapp EL; Tan L; Miranda E; Marciniak SJ; Lomas DA
Hepatology; 2013 May; 57(5):2049-60. PubMed ID: 23197448
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
16. In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).
Tambunan US; Bramantya N; Parikesit AA
BMC Bioinformatics; 2011; 12 Suppl 13(Suppl 13):S23. PubMed ID: 22373132
[TBL] [Abstract][Full Text] [Related]
17. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
Choi SE; Weerasinghe SV; Pflum MK
Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
19. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
